Edgard Vera Tapia, MD
Nephrology · Victorville, CANPI 1235127515
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by CSL Behring at 33.3% of the total. Reporting peaked in 2024 at $3,883 and has fallen 89.6% since, to $404 in 2025.
Across 179 payments — averaging $39.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$2K
- Eli Lilly$2K
- Akebia Therapeutics Inc$731
- Mallinckrodt Hospital Products Inc.$421
- Amgen$400
- AstraZeneca$303
- plus $1K from 15 others
Across 247 payments — averaging $7568.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$604K
- CSL Behring$450K
- Eli Lilly$408K
- Vertex$156K
- Boehringer Ingelheim$101K
- Boehringer Ingelheim International GmbH$98K
- plus $51K from 4 others
What the payments were for
- Travel & lodging$3,38748%
- Food & beverage$3,49250%
- Education$1492%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 9 | $2,341 |
| Eli Lilly | 26 | $1,576 |
| Akebia Therapeutics Inc | 42 | $731 |
| Mallinckrodt Hospital Products Inc. | 17 | $421 |
| Amgen(2 entities) | 17 | $400 |
| AstraZeneca(2 entities) | 15 | $303 |
| GSK | 9 | $222 |
| Vifor Pharma, Inc. | 9 | $219 |
| Otsuka America Pharmaceutical, Inc. | 6 | $167 |
| Novo Nordisk | 3 | $142 |
| Bayer | 6 | $102 |
| Ardelyx, Inc. | 4 | $90 |
| Fresenius USA Marketing, Inc. | 4 | $59 |
| Mallinckrodt Enterprises LLC | 2 | $51 |
| Johnson & Johnson | 2 | $46 |
| Apellis Pharmaceuticals, Inc. | 2 | $41 |
| Aurinia Pharma U.S., Inc. | 2 | $36 |
| Novartis | 1 | $30 |
| Boehringer Ingelheim | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,029 in reported general payments places this provider in the 85th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 295 | $490,849 |
| Sevelamer Hcl | 257 | $350,950 |
| FarxigaDapagliflozin Propanediol | 237 | $145,785 |
| Dermacinrx LidogelLidocaine Hcl | 70 | $143,703 |
| XphozahTenapanor Hcl | 37 | $131,062 |
| VeltassaPatiromer Calcium Sorbitex | 125 | $118,282 |
| VelphoroSucroferric Oxyhydroxide | 40 | $109,778 |
| JardianceEmpagliflozin | 91 | $66,167 |
| LokelmaSodium Zirconium Cyclosilicate | 89 | $63,536 |
| KerendiaFinerenone | 75 | $59,066 |
| ProsolParenteral Amino Acid 20% No.1 | 266 | $43,620 |
| DapagliflozinDapagliflozin Propanediol | 80 | $42,320 |
| InvokanaCanagliflozin | 29 | $22,524 |
| Sevelamer Carbonate | 150 | $21,604 |
| TrulicityDulaglutide | 22 | $20,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Akebia Therapeutics IncAuryxia | $731 | $490,849295 claims |
| AstraZenecaFarxiga, Lokelma | $303 | $209,321326 claims |
| Fresenius USA Marketing, Inc.Velphoro | $59 | $109,77840 claims |
| Boehringer IngelheimJardiance, Tradjenta | $23 | $81,233120 claims |
| BayerKerendia | $102 | $59,06675 claims |
| Johnson & JohnsonInvokana | $46 | $22,52429 claims |
| Novo NordiskOzempic | $142 | $19,09418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,341 nephrology providers in California.
Other nephrology in Victorville
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.